<DOC>
	<DOCNO>NCT02797041</DOCNO>
	<brief_summary>This observational , non-interventional , retrospective , multicenter , national study focus collect information effectiveness safety bortezomib re-use first relapse MM patient already treat first line bortezomib-based regimen , re-challenged drug accord current clinical practice and/or Italian SIE/SIES/GITMO , IMWG and/or NCCN Guidelines/Treatment Recommendations . Data collect retrospectively approximately 25 haematologic/oncologic site Italy . Approximately , data 100 patient collect .</brief_summary>
	<brief_title>Bortezomib First Salvage Therapy Myeloma Patients Previously Exposed Bortezomib Initial Treatment .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients satisfy follow criterion enclose study : Age â‰¥ 18 year old Patients documented multiple myeloma receive bortezomibbased regimen first line treatment ( clinical practice clinical trial ) even follow ASCT ( Autologous stem cell transplantation ) first line treatment 's clinical biochemical relapse receive bortezomibbased treatment accord current clinical practice and/or Italian Societies Hematology ( SIE ) , Experimental Hematology ( SIES ) Transplantation ( GITMO ) , International Myeloma Working group ( IMWG ) and/or National Cancer Comprehensive Cancer Network ( NCCN ) guidelines/treatment recommendation . Signed Informed Consent form feasible Patients treat bortezomib first line therapy and/or second line therapy Patients one relapse bortezomib reuse Patients unable understand sign Informed Consent form ( see exception list section 8 `` Informed consent '' ) Patients receive bortezomib relapse combination investigational drug notapproved .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Relapsed multiple myeloma</keyword>
	<keyword>Rechallenge</keyword>
</DOC>